SINOPHARM (01099): China National Accord Medicines Corporation (000028.SZ) expects the net profit attributable to the parent in 2025 to be approximately 10.55 billion to 12.15 billion yuan, a year-on-year increase of 64.20% to 89.11%.

07:17 26/01/2026

China National Pharmaceutical Group (01099) announced that it is expected that China National Pharmaceutical Group (000028.SZ) will achieve a net profit attributable to the shareholders of the listed company of 10.55 billion to 12.15 billion yuan in 2025, a year-on-year increase of 64.20% to 89.11%. It is expected that the net profit attributable to the shareholders of the listed company after deducting non-recurring gains and losses will be 9.96 billion to 11.56 billion yuan in 2025, a year-on-year increase of 71.38% to 98.91%.

SINOPHARM (01099) announced that China National Accord Medicines Corporation (000028.SZ) is expected to achieve a net profit attributable to shareholders of the listed company of 10.55 billion to 12.15 billion yuan in 2025, a year-on-year increase of 64.20% to 89.11%. It is expected to achieve a net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, of 9.96 billion to 11.56 billion yuan in 2025, a year-on-year increase of 71.38% to 98.91%.

Brokerage morning meeting highlights | Prosperity is the core, adhere to the "technology + resources" dual mainline

ASCLETIS-B (01672) announced that the first batch of subjects in the 13-week Phase II study of the oral small molecule GLP-1R agonist ASC30 for the treatment of diabetes has been dosed in the United States.

On January 23, BEKE-W (02423) spent 3 million US dollars to repurchase 492,000 shares.

Brokerage morning meeting highlights | Prosperity is the core, adhere to the "technology + resources" dual mainline

On January 23, BEKE-W (02423) spent 3 million US dollars to repurchase 492,000 shares.